For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251023:nRSW5779Ea&default-theme=true
RNS Number : 5779E IMI PLC 23 October 2025
23 October 2025
IMI plc
("IMI" or the "Company")
Statement Regarding Shareholder Consultation Following the 2025 Annual General
Meeting
At the Company's Annual General Meeting ("AGM") held on 8 May 2025, all
proposed resolutions were duly passed by shareholders. However, Special
Resolution B, relating to the authority to allot securities for cash for
specific financing purposes, received 78.25% support, falling below the 80%
threshold outlined in the UK Corporate Governance Code (the Code) for enhanced
shareholder engagement.
In line with the Code, the Company contacted shareholders who were understood
to have voted against the resolution to seek their views and better understand
any concerns. Feedback received indicated that the lower level of support was
primarily driven by institutional voting policies and concerns around
potential dilution, particularly in the absence of a defined transaction for
which the authority would be exercised.
The resolution was consistent with the Pre-Emption Group's 2022 Statement of
Principles regarding the disapplication of pre-emption rights. The Board
considered the flexibility afforded by the resolution to be in the best
interests of the Company and its shareholders. Nonetheless, the Board remains
committed to ongoing dialogue with shareholders and will continue to review
its approach in this area. A further update will be provided in the Company's
2025 Annual Report. The Board is grateful to shareholders for their engagement
and constructive feedback.
Enquiries to:
IMI
Edward Hann, Head of Investor
Relations Tel: 07977
354 810
Fran Burge, Deputy Company
Secretary Tel:
0121 717 3700
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCFIFETIILVFIE
Copyright 2019 Regulatory News Service, all rights reserved